Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013 (2013), Article ID 732126, 13 pages
http://dx.doi.org/10.1155/2013/732126
Research Article

Interaction of Veratrum nigrum with Panax ginseng against Obesity: A Sang-ban Relationship

1College of Korean Medicine, Institute of Korean Medicine, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-Gu, Seoul 130701, Republic of Korea
2Department of Oriental Pharmacy, College of Pharmacy, Wonkwang University, 460 Iksandae-ro, Iksan, Jeonbuk 570749, Republic of Korea
3Department of Cosmeceutical Science, Daegu Haany University, 1 Haanydaero, Gyeongsan-si, Gyeongsangbuk-Do 712715, Republic of Korea

Received 2 April 2013; Revised 18 July 2013; Accepted 19 July 2013

Academic Editor: Seong-Gyu Ko

Copyright © 2013 Jinbong Park et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. WHO, “Global Strategy on Diet (Physical Activity and Health),” 2009.
  2. D. W. Haslam and W. P. T. James, “Obesity,” Lancet, vol. 366, no. 9492, pp. 1197–1209, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. I. S. Farooqi and S. O'Rahilly, “Genetic factors in human obesity,” Obesity Reviews, vol. 8, no. 1, pp. 37–40, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Garrow, “Treatment for obesity,” Lancet, vol. 351, no. 9115, p. 1590, 1998. View at Google Scholar · View at Scopus
  5. J. A. Pospisilik, D. Schramek, H. Schnidar et al., “Drosophila genome-wide obesity screen reveals hedgehog as a determinant of brown versus white adipose cell fate,” Cell, vol. 140, no. 1, pp. 148–160, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Tontonoz and B. M. Spiegelman, “Fat and beyond: the diverse biology of PPARγ,” Annual Review of Biochemistry, vol. 77, pp. 289–312, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Salma, H. Xiao, and A. N. Imbalzano, “Temporal recruitment of CCAAT/enhancer-binding proteins to early and late adipogenic promoters in vivo,” Journal of Molecular Endocrinology, vol. 36, no. 1, pp. 139–151, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. Q.-Q. Tang, M. Grønborg, H. Huang et al., “Sequential phosphorylation of CCAAT enhancer-binding protein β by MAPK and glycogen synthase kinase 3β is required for adipogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 28, pp. 9766–9771, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. Z. Cao, R. M. Umek, and S. L. McKnight, “Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells,” Genes and Development, vol. 5, no. 9, pp. 1538–1552, 1991. View at Google Scholar · View at Scopus
  10. J. K. Hamm, B. H. Park, and S. R. Farmer, “A role for C/EBPbeta in regulating peroxisome proliferator-activated receptor gamma activity during adipogenesis in 3T3-L1 preadipocytes,” Journal of Biological Chemistry, vol. 276, no. 21, pp. 18464–18471, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. Z. Wu, E. D. Rosen, R. Brun et al., “Cross-regulation of C/EBP alpha and PPAR gamma controls the transcriptional pathway of adipogenesis and insulin sensitivity,” Molecular Cell, vol. 3, no. 2, pp. 151–158, 1999. View at Google Scholar
  12. C. K. Park, “Huangdi's internal classic,” 2005.
  13. J. Hur, “Dongeuibogam,” 1991.
  14. A. S. Attele, J. A. Wu, and C.-S. Yuan, “Ginseng pharmacology: multiple constituents and multiple actions,” Biochemical Pharmacology, vol. 58, no. 11, pp. 1685–1693, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. M. O'Hara, D. Kiefer, K. Farrell, and K. Kemper, “A review of 12 commonly used medicinal herbs,” Archives of Family Medicine, vol. 7, no. 6, pp. 523–536, 1998. View at Google Scholar · View at Scopus
  16. S. N. Yun, S. J. Moon, S. K. Ko, B. O. Im, and S. H. Chung, “Wild ginseng prevents the onset of high-fat diet induced hyperglycemia and obesity in ICR mice,” Archives of Pharmacal Research, vol. 27, no. 7, pp. 790–796, 2004. View at Google Scholar · View at Scopus
  17. E. A. Sotaniemi, E. Haapakoski, and A. Rautio, “Ginseng therapy in non-insulin-dependent diabetic patients. Effects of psychophysical performance, glucose homeostasis, serum lipids, serum aminoterminalpropeptide concentration, and body weight,” Diabetes Care, vol. 18, no. 10, pp. 1373–1375, 1995. View at Google Scholar · View at Scopus
  18. A. A. Qureshi, N. Abuirmeileh, and Z. Z. Din, “Suppression of cholesterogenesis and reduction of LDL cholesterol by dietary ginseng and its fractions in chicken liver,” Atherosclerosis, vol. 48, no. 1, pp. 81–94, 1983. View at Google Scholar · View at Scopus
  19. S.-H. Kim and K.-S. Park, “Effects of Panax ginseng extract on lipid metabolism in humans,” Pharmacological Research, vol. 48, no. 5, pp. 511–513, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. V. Vuksan and J. L. Sievenpiper, “Herbal remedies in the management of diabetes: lessons learned from the study of ginseng,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 15, no. 3, pp. 149–160, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. A. R. Toogood, “Gardener's Encyclopedia of Perennials,” 1989.
  22. D. G. Barceloux, “Medical Toxicology of Natural Substances,” 2008.
  23. H. Wang, S.-Y. Li, C.-K. Zhao, and X. Zeng, “A system for screening agonists targeting β2- adrenoceptor from Chinese medicinal herbs,” Journal of Zhejiang University, vol. 10, no. 4, pp. 243–250, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Wang, W. Li, and Y. Liu, “Hypotensive effect and toxicology of total alkaloids and veratramine from roots and rhizomes of Veratrum nigrum L. in spontaneously hypertensive rats,” Pharmazie, vol. 63, no. 8, pp. 606–610, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. Z.-Z. Wang, W.-J. Zhao, X.-S. Zhang et al., “Protection of Veratrum nigrum L. var. ussuriense Nakai alkaloids against ischema-reperfusion injury of the rat liver,” World Journal of Gastroenterology, vol. 13, no. 4, pp. 564–571, 2007. View at Google Scholar · View at Scopus
  26. R. Jin, B. Zhang, C.-M. Xue, S.-M. Liu, Q. Zhao, and K. Li, “Classification of 365 Chinese medicines in Shennong's Materia Medica Classic based on a semi-supervised incremental clustering method,” Journal of Chinese Integrative Medicine, vol. 9, no. 6, pp. 665–674, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. B. Pitt, G. B. John Mancini, S. G. Ellis, H. S. Rosman, J.-S. Park, and M. E. McGovern, “Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events,” Journal of the American College of Cardiology, vol. 26, no. 5, pp. 1133–1139, 1995. View at Publisher · View at Google Scholar · View at Scopus
  28. W. T. Friedewald, R. I. Levy, and D. S. Fredrickson, “Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge,” Clinical Chemistry, vol. 18, no. 6, pp. 499–502, 1972. View at Google Scholar · View at Scopus
  29. D. C. Woods, C. Alvarez, and A. L. Johnson, “Cisplatin-mediated sensitivity to TRAIL-induced cell death in human granulosa tumor cells,” Gynecologic Oncology, vol. 108, pp. 632–640, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. J. L. Ramirez-Zacarias, F. Castro-Munozledo, and W. Kuri-Harcuch, “Quantitation of adipose conversion and triglycerides by staining intracytoplasmic lipids with oil red O,” Histochemistry, vol. 97, no. 6, pp. 493–497, 1992. View at Google Scholar · View at Scopus
  31. M. M. Bradford, “A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding,” Analytical Biochemistry, vol. 72, no. 1-2, pp. 248–254, 1976. View at Google Scholar · View at Scopus
  32. J. Shepherd, S. M. Cobbe, I. Ford et al., “Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia,” New England Journal of Medicine, vol. 333, no. 20, pp. 1301–1307, 1995. View at Publisher · View at Google Scholar · View at Scopus
  33. F. M. Sacks, M. A. Pfeffer, L. A. Moye et al., “The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels,” New England Journal of Medicine, vol. 335, no. 14, pp. 1001–1009, 1996. View at Publisher · View at Google Scholar · View at Scopus
  34. J. R. Downs, M. Clearfield, S. Weis et al., “Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS,” Journal of the American Medical Association, vol. 279, no. 20, pp. 1615–1622, 1998. View at Publisher · View at Google Scholar · View at Scopus
  35. F. Paccaud, V. Schlüter-Fasmeyer, V. Wietlisbach, and P. Bovet, “Dyslipidemia and abdominal obesityan assessment in three general populations,” Journal of Clinical Epidemiology, vol. 53, no. 4, pp. 393–400, 2000. View at Publisher · View at Google Scholar · View at Scopus
  36. N.-H. Kim, S.-K. Choi, S.-J. Kim et al., “Green tea seed oil reduces weight gain in C57BL/6J mice and influences adipocyte differentiation by suppressing peroxisome proliferator-activated receptor-γ,” Pflugers Archiv European Journal of Physiology, vol. 457, no. 2, pp. 293–302, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. L. Fajas, “Adipogenesis: a cross-talk between cell proliferation and cell differentiation,” Annals of Medicine, vol. 35, no. 2, pp. 79–85, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. E. D. Rosen, C. J. Walkey, P. Puigserver, and B. M. Spiegelman, “Transcriptional regulation of adipogenesis,” Genes and Development, vol. 14, no. 11, pp. 1293–1307, 2000. View at Google Scholar · View at Scopus
  39. D. Shao and M. A. Lazar, “Peroxisome proliferator activated receptor γ, CCAAT/enhancer-binding protein α, and cell cycle status regulate the commitment to adipocyte differentiation,” Journal of Biological Chemistry, vol. 272, no. 34, pp. 21473–21478, 1997. View at Publisher · View at Google Scholar · View at Scopus
  40. E. M. Williamson, “Synergy and other interactions in phytomedicines,” Phytomedicine, vol. 8, no. 5, pp. 401–409, 2001. View at Google Scholar · View at Scopus
  41. G. Wei and X. Zheng, “A survey of the studies on compatible law of ingredients in Chinese herbal prescriptions,” Journal of Traditional Chinese Medicine, vol. 28, no. 3, pp. 223–227, 2008. View at Google Scholar
  42. S. Li, B. Zhang, D. Jiang, Y. Wei, and N. Zhang, “Herb network construction and co-module analysis for uncovering the combination rule of traditional Chinese herbal formulae,” BMC Bioinformatics, vol. 11, no. 11, supplement, article S6, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Su, Y. Hua, Y. Wang et al., “Evaluation of the anti-inflammatory and analgesic properties of individual and combined extracts from Commiphora myrrha, and Boswellia carterii,” Journal of Ethnopharmacology, vol. 139, no. 2, pp. 649–656, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. H. Wagner and G. Ulrich-Merzenich, “Synergy research: approaching a new generation of phytopharmaceuticals,” Phytomedicine, vol. 16, no. 2-3, pp. 97–110, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. H. Wagner, “Synergy research: a new approach to evaluating the efficacy of herbal mono-drug extracts and their combinations,” Natural Product Communications, vol. 4, no. 2, pp. 303–304, 2009. View at Google Scholar · View at Scopus
  46. H. Wagner, “Synergy research: approaching a new generation of phytopharmaceuticals,” Fitoterapia, vol. 82, no. 1, pp. 34–37, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. B. M. Spiegelman and J. S. Flier, “Obesity and the regulation of energy balance,” Cell, vol. 104, no. 4, pp. 531–543, 2001. View at Publisher · View at Google Scholar · View at Scopus
  48. A. H. Mokdad, E. S. Ford, B. A. Bowman et al., “Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001,” Journal of the American Medical Association, vol. 289, no. 1, pp. 76–79, 2003. View at Publisher · View at Google Scholar · View at Scopus
  49. C. A. Luque and J. A. Rey, “Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity,” Annals of Pharmacotherapy, vol. 33, no. 9, pp. 968–978, 1999. View at Publisher · View at Google Scholar · View at Scopus
  50. A. M. Heck, J. A. Yanovski, and K. A. Calis, “Orlistat, a new lipase inhibitor for the management of obesity,” Pharmacotherapy, vol. 20, no. 3, pp. 270–279, 2000. View at Google Scholar · View at Scopus
  51. C. E. Leite, C. A. Mocelin, G. O. Petersen, M. B. Leal, and F. V. Thiesen, “Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity,” Pharmacological Reports, vol. 61, no. 2, pp. 217–224, 2009. View at Google Scholar · View at Scopus